Drug · DIN 02378590
CAPRELSA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 7, 2026; first marketed February 23, 2012.
- Drug Identification Number (DIN)
- 02378590
- Company (DIN owner)
- Esteve Pharmaceuticals S.A.Barcelona, Barcelona, Spain
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Vandetanib L01EX04
- Class
- Human
- Record last updated
- October 9, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| VANDETANIB | 300 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 7, 2026: NOC 38421New Drug Submission (NDS) · Administrative: Change in product ownership
- April 5, 2024: NOC 33018New Drug Submission (NDS) · Administrative: Change in Product Ownership
- May 8, 2017: NOC 19274Supplement to a New Drug Submission (SNDS) · Safety updates to the product monograph in response to an advisement letter pertaining to new adverse events
- July 8, 2016: NOC 18262New Drug Submission (NDS) · Transfer of drug identification numbers
- January 12, 2012: NOC 12921New Drug Submission (NDS)
Other DINs named CAPRELSA
- DIN 02378582 · Marketed